{
  "source": "PA-Notification-Lumakras.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1360-4\nProgram Prior Authorization/Notification\nMedication Lumakras™ (sotorasib)\nP&T Approval Date 7/2021, 7/2022, 7/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nLumakras (sotorasib) is an inhibitor of the RAS GTPase family indicated for the treatment of\nadult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung\ncancer (NSCLC) who have received at least one prior systemic therapy. The National\nComprehensive Cancer Network (NCCN) recommends the use of Lumakras as subsequent\ntherapy for the treatment of KRAS G12C-mutated recurrent, advanced, or metastatic NSCLC.\nNCCN also recommends the use of Lumakras as subsequent therapy for the treatment of KRAS\nG12C-mutated pancreatic adenocarcinoma, ampullary adenocarcinoma, colon cancer, and rectal\ncancer.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Lumakras will be approved based on the following criterion:\na. Member is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Non-Small Cell Lung Cancer (NSCLC)\n1. Initial Authorization\na. Lumakras will be approved based on all of the following criteria:\n(1) Diagnosis of non-small cell lung cancer (NSCLC)\n-AND-\n© 2024 UnitedHealthcare Services Inc.\n1\n(2) Disease is one of the following:\n(a) Recurrent\n(b) Advanced\n(c) Metastatic\n-AND-\n(3) Tumor is KRAS G12C-mutated\n-AND-\n(4) Patient has received at least one prior systemic therapy (e.g., immune\ncheckpoint ",
    "ase is one of the following:\n(a) Recurrent\n(b) Advanced\n(c) Metastatic\n-AND-\n(3) Tumor is KRAS G12C-mutated\n-AND-\n(4) Patient has received at least one prior systemic therapy (e.g., immune\ncheckpoint inhibitor, platinum-based chemotherapy)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Lumakras will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Lumakras\ntherapy\nAuthorization will be issued for 12 months.\nC. Pancreatic Adenocarcinoma\n1. Initial Authorization\na. Lumakras will be approved based on all of the following criteria:\n(1) Diagnosis of pancreatic adenocarcinoma\n-AND-\n(2) Disease is one of the following:\n(a) Recurrent\n(b) Advanced\n(c) Metastatic\n-AND-\n(3) Tumor is KRAS G12C-mutated\n-AND-\n(4) Patient has received at least one prior systemic therapy (e.g., immune\ncheckpoint inhibitor, platinum-based chemotherapy)\n© 2024 UnitedHealthcare Services Inc.\n2\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Lumakras will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Lumakras\ntherapy\nAuthorization will be issued for 12 months.\nD. Ampullary Adenocarcinoma\n1. Initial Authorization\na. Lumakras will be approved based on all of the following criteria:\n(1) Diagnosis of ampullary adenocarcinoma\n-AND-\n(2) Disease is one of the following:\n(a) Recurrent\n(b) Advanced\n(c) Metastatic\n-AND-\n(3) Tumor is KRAS G12C-mutation positive\n-AND-\n(4) Patient has received at least one prior systemic therapy (e.g., immune\ncheckpoint inhibitor, platinum-based chemotherapy)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Lumakras will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Lumakras\ntherapy\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services Inc.\n3\nE. Colorectal Cancer\n1. Initial Authorization\na. Lumakras will be appr",
    "progressive disease while on Lumakras\ntherapy\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services Inc.\n3\nE. Colorectal Cancer\n1. Initial Authorization\na. Lumakras will be approved based on all of the following criteria:\n(1) Diagnosis of one of the following:\n(a) Colon Cancer\n(b) Rectal Cancer\n-AND-\n(2) Disease is one of the following:\n(a) Recurrent\n(b) Advanced\n(c) Metastatic\n-AND-\n(3) Tumor is KRAS G12C-mutation positive\n-AND-\n(4) Patient has received at least one prior systemic therapy (e.g., immune\ncheckpoint inhibitor, platinum-based chemotherapy)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Lumakras will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Lumakras\ntherapy\nAuthorization will be issued for 12 months.\nF. NCCN Recommended Regimens\na. The drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2024 UnitedHealthcare Services Inc.\n4\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Lumakras [package insert]. Thousand Oaks, CA: Amgen, Inc; April 2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org. May 16, 2024.\nProgram Prior Authorization/Notification – Lumakras (sotorasib)\nChange Control\n7/2021 New",
    " 2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org. May 16, 2024.\nProgram Prior Authorization/Notification – Lumakras (sotorasib)\nChange Control\n7/2021 New program.\n7/2022 Annual review. Expanded coverage criteria to include “recurrent”\ndisease per current NCCN guidelines. Added state mandate disclaimer\nand updated references.\n7/2023 Annual review. Updated background and criteria to include coverage of\npancreatic adenocarcinoma per NCCN guidelines. Updated references.\n7/2024 Annual review. Added criteria for ampullary adenocarcinoma, colon\ncancer, and rectal cancer per NCCN guidelines. Updated background\nand references.\n© 2024 UnitedHealthcare Services Inc.\n5"
  ]
}